Decibel Cannabis Company Inc.

OTCPK:DBCC.F Stock Report

Market Cap: US$47.2m

Decibel Cannabis Valuation

Is DBCC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DBCC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$1.57
Fair Value
94.8% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: DBCC.F ($0.08) is trading below our estimate of fair value ($1.57)

Significantly Below Fair Value: DBCC.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DBCC.F?

Key metric: As DBCC.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DBCC.F. This is calculated by dividing DBCC.F's market cap by their current earnings.
What is DBCC.F's PE Ratio?
PE Ratio5.7x
EarningsCA$11.71m
Market CapCA$66.34m

Price to Earnings Ratio vs Peers

How does DBCC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for DBCC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.8x
BTMD biote
3x-52.22%US$116.0m
ZYBT Zhengye Biotechnology Holding
63.8xn/aUS$111.4m
ORMP Oramed Pharmaceuticals
2.6xn/aUS$114.6m
SIGA SIGA Technologies
5.8x61.27%US$426.1m
DBCC.F Decibel Cannabis
5.7x34.72%US$66.3m

Price-To-Earnings vs Peers: DBCC.F is good value based on its Price-To-Earnings Ratio (5.7x) compared to the peer average (18.8x).

Price to Earnings Ratio vs Industry

How does DBCC.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
4x19.13%US$1.95b
NDOI Endo
0.3xn/aUS$1.76b
CRMD CorMedix
4.7x5.20%US$740.62m
BTMD biote
3x-52.22%US$115.98m
DBCC.F 5.7xIndustry Avg. 20.6xNo. of Companies10PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DBCC.F is good value based on its Price-To-Earnings Ratio (5.7x) compared to the US Pharmaceuticals industry average (20.5x).

Price to Earnings Ratio vs Fair Ratio

What is DBCC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DBCC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.7x
Fair PE Ratio21.8x

Price-To-Earnings vs Fair Ratio: DBCC.F is good value based on its Price-To-Earnings Ratio (5.7x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DBCC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.082
US$0.19
+131.58%
8.84%US$0.21US$0.18n/a3
Nov ’26US$0.10
US$0.19
+88.55%
8.84%US$0.22US$0.18n/a3
Oct ’26US$0.10
US$0.19
+88.36%
8.84%US$0.22US$0.18n/a3
Sep ’26US$0.096
US$0.19
+99.91%
8.84%US$0.22US$0.18n/a3
Aug ’26US$0.063
US$0.17
+170.75%
10.10%US$0.18US$0.15n/a3
Jul ’26US$0.051
US$0.17
+231.98%
10.10%US$0.18US$0.15n/a3
Jun ’26US$0.05
US$0.17
+236.56%
10.10%US$0.18US$0.14n/a3
May ’26US$0.049
US$0.19
+294.64%
23.38%US$0.25US$0.14n/a3
Apr ’26US$0.044
US$0.18
+317.52%
23.38%US$0.24US$0.14n/a3
Mar ’26US$0.051
US$0.18
+261.58%
23.38%US$0.24US$0.14n/a3
Feb ’26US$0.052
US$0.18
+253.81%
23.38%US$0.24US$0.14n/a3
Jan ’26US$0.048
US$0.21
+334.01%
23.57%US$0.24US$0.14n/a3
Dec ’25US$0.045
US$0.21
+379.09%
23.57%US$0.25US$0.14n/a3
Nov ’25US$0.053
US$0.19
+262.99%
23.38%US$0.25US$0.14US$0.103
Oct ’25US$0.041
US$0.23
+460.35%
26.84%US$0.29US$0.15US$0.103
Sep ’25US$0.048
US$0.23
+384.15%
26.84%US$0.29US$0.15US$0.0963
Aug ’25US$0.044
US$0.27
+516.95%
28.02%US$0.37US$0.18US$0.0633
Jul ’25US$0.048
US$0.31
+548.57%
17.65%US$0.37US$0.26US$0.0512
Jun ’25US$0.052
US$0.27
+413.17%
28.02%US$0.36US$0.18US$0.053
May ’25US$0.09
US$0.28
+208.68%
22.17%US$0.36US$0.22US$0.0493
Apr ’25US$0.09
US$0.34
+275.10%
24.00%US$0.45US$0.26US$0.0443
Mar ’25US$0.081
US$0.34
+317.12%
24.00%US$0.45US$0.26US$0.0513
Feb ’25US$0.097
US$0.34
+247.02%
24.00%US$0.45US$0.26US$0.0523
Jan ’25US$0.098
US$0.34
+242.21%
24.00%US$0.45US$0.26US$0.0483
Dec ’24US$0.11
US$0.36
+242.85%
20.00%US$0.43US$0.29US$0.0452
Nov ’24US$0.10
US$0.36
+255.66%
20.00%US$0.43US$0.29US$0.0532
US$0.19
Fair Value
56.9% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/26 09:52
End of Day Share Price 2025/11/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Decibel Cannabis Company Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frederico Yokota Choucair GomesATB Capital Markets
Kimberly Thompson-HedlinCanaccord Genuity
Neal GilmerHaywood Securities Inc.